A Comparison of IDeg + IAsp Versus IDet + IAsp in Subjects with Type 1 Diabetes: Subgroup Analysis of Japanese Subjects

Overview

Journal Diabetol Int

Specialty Endocrinology

Date 2019 Jan 4

PMID 30603293

Citations 1

Authors

Y Ono

T Nishida

J Hyllested-Winge

H Seino

T Sasaki

Affiliations

Soon will be listed here.

Abstract

Objective: Efficacy and safety were compared between insulin degludec (IDeg) once daily (OD) in combination with mealtime insulin aspart (IAsp) and insulin detemir (IDet) OD or twice daily (BID) in combination with mealtime IAsp in Japanese subjects with type 1 diabetes mellitus (T1DM).

Materials And Methods: This was a post hoc analysis of a multinational, controlled, open-label, parallel-group, treat-to-target trial that randomised adults [aged ≥18 years (≥20 years for Japan)] with T1DM for ≥12 months to basal IDeg OD ( = 124) or IDet ( = 62), both with mealtime bolus IAsp. The IDet dosing was adjusted to BID if required at ≥8 weeks.

Results: The estimated mean change in HbA from baseline to week 26 (the primary outcome measure) was -1.03 % in the IDeg + IAsp group and -0.94 % in the IDet + IAsp group (mean estimated treatment difference [ETD] -0.09; 95 % confidence interval [CI] -0.29, 0.10). Significantly greater reductions in fasting plasma glucose were observed in the IDeg + IAsp group (mean ETD -39.36 mg/dL; 95 % CI -56.04, -22.68). Both groups had similar rates of confirmed hypoglycaemia (59.9 and 59.2 per patient-year of exposure [PYE] with IDeg + IAsp and IDet + IAsp, respectively). Rates of nocturnal confirmed hypoglycaemia were significantly lower with IDeg + IAsp than with IDet + IAsp (5.2 vs 9.5 episodes per PYE; estimated ratio 0.48; 95 % CI 0.31, 0.75). Adverse event profiles were similar.

Conclusion: The findings were consistent with those of the global trial population. IDeg + IAsp may represent an improvement on current standard treatments for Japanese patients with T1DM.

Citing Articles

(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.

Hemmingsen B, Metzendorf M, Richter B Cochrane Database Syst Rev. 2021; 3:CD013498.

PMID: 33662147 PMC: 8094220. DOI: 10.1002/14651858.CD013498.pub2.

References

Kawasaki E, Matsuura N, Eguchi K . Type 1 diabetes in Japan. Diabetologia. 2006; 49(5):828-36. DOI: 10.1007/s00125-006-0213-8. View

Kanatsuka A, Kawai K, Hirao K, Oishi M, Takagi H, Kobayashi M . Actual usage and clinical effectiveness of insulin preparations in patients with Type 1 diabetes mellitus in Japan: CoDiC-based analysis of clinical data obtained at multiple institutions (JDDM 3). Diabetes Res Clin Pract. 2006; 72(3):277-83. DOI: 10.1016/j.diabres.2005.03.040. View

Kobayashi M, Yamazaki K, Hirao K, Oishi M, Kanatsuka A, Yamauchi M . The status of diabetes control and antidiabetic drug therapy in Japan--a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1). Diabetes Res Clin Pract. 2006; 73(2):198-204. DOI: 10.1016/j.diabres.2006.01.013. View

Park Y . Why is type 1 diabetes uncommon in Asia?. Ann N Y Acad Sci. 2006; 1079:31-40. DOI: 10.1196/annals.1375.005. View

Bartley P, Bogoev M, Larsen J, Philotheou A . Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med. 2008; 25(4):442-9. PMC: 2327220. DOI: 10.1111/j.1464-5491.2007.02407.x. View

Birkeland K, Home P, Wendisch U, Ratner R, Johansen T, Endahl L . Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care. 2011; 34(3):661-5. PMC: 3041203. DOI: 10.2337/dc10-1925. View

Peyrot M, Barnett A, Meneghini L, Schumm-Draeger P . Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study. Diabet Med. 2012; 29(5):682-9. PMC: 3433794. DOI: 10.1111/j.1464-5491.2012.03605.x. View

Heller S, Buse J, Fisher M, Garg S, Marre M, Merker L . Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012; 379(9825):1489-97. DOI: 10.1016/S0140-6736(12)60204-9. View

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H . Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012; 14(9):859-64. DOI: 10.1111/j.1463-1326.2012.01627.x. View

10.

Hirsch I, Bode B, Courreges J, Dykiel P, Franek E, Hermansen K . Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial. Diabetes Care. 2012; 35(11):2174-81. PMC: 3476910. DOI: 10.2337/dc11-2503. View

11.

Ratner R, Gough S, Mathieu C, Del Prato S, Bode B, Mersebach H . Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2012; 15(2):175-84. PMC: 3752969. DOI: 10.1111/dom.12032. View

12.

Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D . Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013; 98(3):1154-62. PMC: 3612802. DOI: 10.1210/jc.2012-3249. View

13.

Bode B, Buse J, Fisher M, Garg S, Marre M, Merker L . Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomized clinical.... Diabet Med. 2013; 30(11):1293-7. PMC: 4264937. DOI: 10.1111/dme.12243. View

14.

Nathan D . The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2013; 37(1):9-16. PMC: 3867999. DOI: 10.2337/dc13-2112. View

15.

Lachin J, Orchard T, Nathan D . Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2013; 37(1):39-43. PMC: 3868002. DOI: 10.2337/dc13-2116. View

16.

Gubitosi-Klug R . The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care. 2013; 37(1):44-9. PMC: 3867991. DOI: 10.2337/dc13-2148. View

17.

Davies M, Gross J, Ono Y, Sasaki T, Bantwal G, Gall M . Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial. Diabetes Obes Metab. 2014; 16(10):922-30. PMC: 4237553. DOI: 10.1111/dom.12298. View

18.

Iwamoto Y, Clauson P, Nishida T, Kaku K . Insulin degludec in Japanese patients with type 1 diabetes mellitus: A randomized controlled trial. J Diabetes Investig. 2014; 4(1):62-8. PMC: 4019289. DOI: 10.1111/j.2040-1124.2012.00240.x. View

19.

Chiang J, Kirkman M, Laffel L, Peters A . Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care. 2014; 37(7):2034-54. PMC: 5865481. DOI: 10.2337/dc14-1140. View